The bill requires the Executive Office of Health and Human Services to submit a quarterly report detailing the projected total costs for pharmaceutical pipeline drugs anticipated to be available for use within the next fiscal year. Specifically, it focuses on drugs identified by the executive office, with a report due that includes the expected utilization of these products over a 12-month period.

In the latest report, the Executive Office has identified 64 pipeline market entries expected to be available between January 1, 2025, and December 31, 2025, with an estimated expenditure of approximately $20 million for all MassHealth members. This marks an increase from a previous estimate of $18.9 million, attributed primarily to a novel cell therapy that is driving the anticipated rise in spending.